AKT1 and prostate cancer: In prostate cancer, PC3 cells treated with luteolin showed poor cellular adhesion as well as increase in cell invasion through the AKT pathway via increasing E‐cadherin expression by inhibiting mouse double minute 2 (mdm2) gene (Zhou et al. 2009).